Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
Add more filters










Publication year range
1.
ACS Appl Mater Interfaces ; 16(15): 18643-18657, 2024 Apr 17.
Article in English | MEDLINE | ID: mdl-38564504

ABSTRACT

Musculoskeletal diseases involving tissue injury comprise tendon, ligament, and muscle injury. Recently, macrophages have been identified as key players in the tendon repair process, but no therapeutic strategy involving dual drug delivery and gene delivery to macrophages has been developed for targeting the two main dysregulated aspects of macrophages in tendinopathy, i.e., inflammation and fibrosis. Herein, the anti-inflammatory and antifibrotic effects of dual-loaded budesonide and serpine1 siRNA lipid-polymer hybrid nanoparticles (LPNs) are evaluated in murine and human macrophage cells. The modulation of the gene and protein expression of factors associated with inflammation and fibrosis in tendinopathy is demonstrated by real time polymerase chain reaction and Western blot. Macrophage polarization to the M2 phenotype and a decrease in the production of pro-inflammatory cytokines are confirmed in macrophage cell lines and primary cells. The increase in the activity of a matrix metalloproteinase involved in tissue remodelling is proven, and studies evaluating the interactions of LPNs with T cells proved that dual-loaded LPNs act specifically on macrophages and do not induce any collateral effects on T cells. Overall, these dual-loaded LPNs are a promising combinatorial therapeutic strategy with immunomodulatory and antifibrotic effects in dysregulated macrophages in the context of tendinopathy.


Subject(s)
Nanoparticles , Tendinopathy , Animals , Humans , Mice , Polymers , RNA, Small Interfering/genetics , Budesonide , Macrophages , Inflammation , Lipids , Fibrosis
2.
ACS Appl Bio Mater ; 6(10): 4269-4276, 2023 10 16.
Article in English | MEDLINE | ID: mdl-37774367

ABSTRACT

Exosomes are natural endogenous extracellular vesicles with phospholipid-based bilayer membrane structures. Due to their unique protein-decorated membrane properties, exosomes have been regarded as promising drug carriers to deliver small molecules and genes. A number of approaches have been developed for exosome-based drug loading. However, the drug loading capability of exosomes is inconsistent, and the effects of loading methods on the therapeutic efficacy have not been investigated in detail. Herein, we developed anti-inflammatory drug-loaded exosomes as an immunomodulatory nanoplatform. Naïve macrophage-derived exosomes (Mϕ-EVs) were loaded with the anti-inflammatory drug mycophenolic acid (MPA) by three major loading methods. Loading into exosomes significantly enhanced anti-inflammatory and antioxidation effects of MPA in vitro compared to free drugs. These findings provide a scientific basis for developing naïve macrophage-secreted exosomes as drug carriers for immunotherapy.


Subject(s)
Extracellular Vesicles , Myoblasts, Cardiac , Mycophenolic Acid/pharmacology , Drug Carriers/chemistry , Macrophages , Anti-Inflammatory Agents
3.
ACS Appl Mater Interfaces ; 15(19): 23012-23023, 2023 May 17.
Article in English | MEDLINE | ID: mdl-37129860

ABSTRACT

Tendinitis is a tendon disorder related to inflammation and pain, due to an injury or overuse of the tissue, which is hypocellular and hypovascular, leading to limited repair which occurs in a disorganized deposition of extracellular matrix that leads to scar formation and fibrosis, ultimately resulting in impaired tendon integrity. Current conventional treatments are limited and often ineffective, highlighting the need for new therapeutic strategies. In this work, acetalated-dextran nanoparticles (AcDEX NPs) loaded with curcumin and coated with tannic acid (TA) are developed to exploit the anti-inflammatory and anti-fibrotic properties of the two compounds. For this purpose, a microfluidic technique was used in order to obtain particles with a precise size distribution, aiming to decrease the batch-to-batch variability for possible future clinical translation. Coating with TA increased not only the stability of the nanosystem in different media but also enhanced the interaction and the cell-uptake in primary human tenocytes and KG-1 macrophages. The nanosystem exhibited good biocompatibility toward these cell types and a good release profile in an inflammatory environment. The efficacy was demonstrated by real-time quantitative polymerase chain reaction, in which the curcumin loaded in the particles showed good anti-inflammatory properties by decreasing the expression of NF-κb and TA-coated NPs showing anti-fibrotic effect, decreasing the gene expression of TGF-ß. Overall, due to the loading of curcumin and TA in the AcDEX NPs, and their synergistic activity, this nanosystem has promising properties for future application in tendinitis.


Subject(s)
Curcumin , Nanoparticles , Humans , Curcumin/pharmacology , Tenocytes , Anti-Inflammatory Agents/pharmacology
4.
Small ; 18(15): e2200449, 2022 04.
Article in English | MEDLINE | ID: mdl-35229498

ABSTRACT

A surface adsorption strategy is developed to enable the engineering of microcomposites featured with ultrahigh loading capacity and precise ratiometric control of co-encapsulated peptides. In this strategy, peptide molecules (insulin, exenatide, and bivalirudin) are formulated into nanoparticles and their surface is decorated with carrier polymers. This polymer layer blocks the phase transfer of peptide nanoparticles from oil to water and, consequently, realizes ultrahigh peptide loading degree (up to 78.9%). After surface decoration, all three nanoparticles are expected to exhibit the properties of adsorbed polymer materials, which enables the co-encapsulation of insulin, exenatide, and bivalirudin with a precise ratiometric control. After solidification of this adsorbed polymer layer, the release of peptides is synchronously prolonged. With the help of encapsulation, insulin achieves 8 days of glycemic control in type 1 diabetic rats with one single injection. The co-delivery of insulin and exenatide (1:1) efficiently controls the glycemic level in type 2 diabetic rats for 8 days. Weekly administration of insulin and exenatide co-encapsulated microcomposite effectively reduces the weight gain and glycosylated hemoglobin level in type 2 diabetic rats. The surface adsorption strategy sets a new paradigm to improve the pharmacokinetic and pharmacological performance of peptides, especially for the combination of peptides.


Subject(s)
Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 2 , Adsorption , Animals , Blood Glucose , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Exenatide/therapeutic use , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Peptides/pharmacology , Polymers/chemistry , Rats
5.
Nano Lett ; 21(22): 9458-9467, 2021 11 24.
Article in English | MEDLINE | ID: mdl-34780176

ABSTRACT

Engineering a system with a high mass fraction of active ingredients, especially water-soluble proteins, is still an ongoing challenge. In this work, we developed a versatile surface camouflage strategy that can engineer systems with an ultrahigh mass fraction of proteins. By formulating protein molecules into nanoparticles, the demand of molecular modification was transformed into a surface camouflage of protein nanoparticles. Thanks to electrostatic attractions and van der Waals interactions, we camouflaged the surface of protein nanoparticles through the adsorption of carrier materials. The adsorption of carrier materials successfully inhibited the phase transfer of insulin, albumin, ß-lactoglobulin, and ovalbumin nanoparticles. As a result, the obtained microcomposites featured with a record of protein encapsulation efficiencies near 100% and a record of protein mass fraction of 77%. After the encapsulation in microcomposites, the insulin revealed a hypoglycemic effect for at least 14 d with one single injection, while that of insulin solution was only ∼4 h.


Subject(s)
Nanoparticles , Adsorption , Insulin , Proteins
6.
Cell Rep ; 35(8): 109131, 2021 05 25.
Article in English | MEDLINE | ID: mdl-34038723

ABSTRACT

Communication between biological components is critical for homeostasis maintenance among the convergence of complicated bio-signals. For therapeutic nanoparticles (NPs), the general lack of effective communication mechanisms with the external cellular environment causes loss of homeostasis, resulting in deprived autonomy, severe macrophage-mediated clearance, and limited tumor accumulation. Here, we develop a multistage signal-interactive system on porous silicon particles through integrating the Self-peptide and Tyr-Ile-Gly-Ser-Arg (YIGSR) peptide into a hierarchical chimeric signaling interface with "don't eat me" and "eat me" signals. This biochemical transceiver can act as both the signal receiver for amantadine to achieve NP transformation and signal conversion as well as the signal source to present different signals sequentially by reversible self-mimicking. Compared with the non-interactive controls, these signal-interactive NPs loaded with AS1411 and tanespimycin (17-AAG) as anticancer drugs improve tumor targeting 2.8-fold and tumor suppression 6.5-fold and showed only 51% accumulation in the liver with restricted hepatic injury.


Subject(s)
Cell Communication/immunology , Nanoparticles/metabolism , Neoplasms/immunology , Humans , Models, Molecular , Neoplasm Staging , Signal Transduction
7.
Adv Drug Deliv Rev ; 174: 576-612, 2021 07.
Article in English | MEDLINE | ID: mdl-34019958

ABSTRACT

Ribonucleic acid interference (RNAi) is an innovative treatment strategy for a myriad of indications. Non-viral synthetic nanoparticles (NPs) have drawn extensive attention as vectors for RNAi due to their potential advantages, including improved safety, high delivery efficiency and economic feasibility. However, the complex natural process of RNAi and the susceptible nature of oligonucleotides render the NPs subject to particular design principles and requirements for practical fabrication. Here, we summarize the requirements and obstacles for fabricating non-viral nano-vectors for efficient RNAi. To address the delivery challenges, we discuss practical guidelines for materials selection and NP synthesis in order to maximize RNA encapsulation efficiency and protection against degradation, and to facilitate the cytosolic release of oligonucleotides. The current status of clinical translation of RNAi-based therapies and further perspectives for reducing the potential side effects are also reviewed.


Subject(s)
Nanoparticles , RNA Interference , RNA, Small Interfering/administration & dosage , Animals , Gene Transfer Techniques , Humans , Oligonucleotides/administration & dosage
8.
ACS Appl Mater Interfaces ; 12(40): 44554-44562, 2020 Oct 07.
Article in English | MEDLINE | ID: mdl-32960566

ABSTRACT

Recently, there has been an increasing interest for utilizing the host immune system to fight against cancer. Moreover, cancer vaccines, which can stimulate the host immune system to respond to cancer in the long term, are being investigated as a promising approach to induce tumor-specific immunity. In this work, we prepared an effective cancer vaccine (denoted as "vacosome") by reconstructing the cancer cell membrane, monophosphoryl lipid A as a toll-like receptor 4 agonist, and egg phosphatidylcholine. The vacosome triggered and enhanced bone marrow dendritic cell maturation as well as stimulated the antitumor response against breast cancer 4T1 cells in vitro. Furthermore, an immune memory was established in BALB/c mice after three-time preimmunization with the vacosome. After that, the immunized mice showed inhibited tumor growth and prolonged survival period (longer than 50 days). Overall, our results demonstrate that the vacosome can be a potential candidate for clinical translation as a cancer vaccine.


Subject(s)
Breast Neoplasms/therapy , Cancer Vaccines/immunology , Lipid A/analogs & derivatives , Animals , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Cancer Vaccines/chemistry , Cell Line, Tumor , Cell Membrane/chemistry , Cell Membrane/immunology , Cell Proliferation , Lipid A/chemistry , Lipid A/immunology , Mice , Mice, Inbred BALB C , Particle Size , Surface Properties
9.
Adv Healthc Mater ; 9(17): e2000529, 2020 09.
Article in English | MEDLINE | ID: mdl-32729247

ABSTRACT

Biohybrid nanosystems represent the cutting-edge research in biofunctionalization of micro- and nano-systems. Their physicochemical properties bring along advantages in the circulation time, camouflaging from the phagocytes, and novel antigens. This is partially a result of the qualitative differences in the protein corona, and the preferential targeting and uptake in homologous cells. However, the effect of the cell membrane on the cellular endocytosis mechanisms and time has not been fully evaluated yet. Here, the effect is assessed by quantitative flow cytometry analysis on the endocytosis of hydrophilic, negatively charged porous silicon nanoparticles and on their membrane-coated counterparts, in the presence of chemical inhibitors of different uptake pathways. Principal component analysis is used to analyze all the data and extrapolate patterns to highlight the cell-specific differences in the endocytosis mechanisms. Furthermore, the differences in the composition of static protein corona between naked and coated particles are investigated together with how these differences affect the interaction with human macrophages. Overall, the presence of the cell membrane only influences the speed and the entity of nanoparticles association with the cells, while there is no direct effect on the endocytosis pathways, composition of protein corona, or any reduction in macrophage-mediated uptake.


Subject(s)
Nanoparticles , Protein Corona , Cell Membrane , Endocytosis , Humans , Porosity , Silicon
10.
Small ; 16(9): e1904673, 2020 03.
Article in English | MEDLINE | ID: mdl-31702878

ABSTRACT

In the past two decades, microfluidics-based particle production is widely applied for multiple biological usages. Compared to conventional bulk methods, microfluidic-assisted particle production shows significant advantages, such as narrower particle size distribution, higher reproducibility, improved encapsulation efficiency, and enhanced scaling-up potency. Herein, an overview of the recent progress of the microfluidics technology for nano-, microparticles or droplet fabrication, and their biological applications is provided. For both nano-, microparticles/droplets, the previously established mechanisms behind particle production via microfluidics and some typical examples during the past five years are discussed. The emerging interdisciplinary technologies based on microfluidics that have produced microparticles or droplets for cellular analysis and artificial cells fabrication are summarized. The potential drawbacks and future perspectives are also briefly discussed.


Subject(s)
Microfluidics , Microfluidics/standards , Microfluidics/trends , Nanoparticles/chemistry , Reproducibility of Results
11.
Nat Commun ; 10(1): 5747, 2019 12 17.
Article in English | MEDLINE | ID: mdl-31848338

ABSTRACT

Virus-based cancer vaccines are nowadays considered an interesting approach in the field of cancer immunotherapy, despite the observation that the majority of the immune responses they elicit are against the virus and not against the tumor. In contrast, targeting tumor associated antigens is effective, however the identification of these antigens remains challenging. Here, we describe ExtraCRAd, a multi-vaccination strategy focused on an oncolytic virus artificially wrapped with tumor cancer membranes carrying tumor antigens. We demonstrate that ExtraCRAd displays increased infectivity and oncolytic effect in vitro and in vivo. We show that this nanoparticle platform controls the growth of aggressive melanoma and lung tumors in vivo both in preventive and therapeutic setting, creating a highly specific anti-cancer immune response. In conclusion, ExtraCRAd might serve as the next generation of personalized cancer vaccines with enhanced features over standard vaccination regimens, representing an alternative way to target cancer.


Subject(s)
Cancer Vaccines/administration & dosage , Immunotherapy/methods , Neoplasms/therapy , Oncolytic Viruses/immunology , Vaccination/methods , Adenoviridae/immunology , Animals , Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Cell Line, Tumor/cytology , Cell Line, Tumor/immunology , Cell Line, Tumor/transplantation , Cell Membrane/immunology , Disease Models, Animal , Female , Humans , Injections, Intralesional , Mice , Nanoparticles/administration & dosage , Neoplasms/immunology , Treatment Outcome , Xenograft Model Antitumor Assays
12.
ACS Nano ; 13(6): 6477-6490, 2019 06 25.
Article in English | MEDLINE | ID: mdl-31100004

ABSTRACT

Recent approaches in the treatment of cancer focus on involving the immune system to control the tumor growth. The administration of immunotherapies, like checkpoint inhibitors, has shown impressive results in the long term survival of patients. Cancer vaccines are being investigated as further tools to prime tumor-specific immunity. Biomaterials show potential as adjuvants in the formulation of vaccines, and biomimetic elements derived from the membrane of tumor cells may widen the range of antigens contained in the vaccine. Here, we show how mice presenting an aggressive melanoma tumor model treated twice with the complete nanovaccine formulation showed control on the tumor progression, while in a less aggressive model, the animals showed remission and control on the tumor progression, with a modification in the immunological profile of the tumor microenvironment. We also prove that co-administration of the nanovaccine together with a checkpoint inhibitor increases the efficacy of the treatment (87.5% of the animals responding, with 2 remissions) compared to the checkpoint inhibitor alone in the B16.OVA model. Our platform thereby shows potential applications as a cancer nanovaccine in combination with the standard clinical care treatment for melanoma cancers.


Subject(s)
Cancer Vaccines/immunology , Melanoma/therapy , Nanoparticles/chemistry , Animals , Antigen-Presenting Cells/immunology , Antigens, Neoplasm/immunology , Cancer Vaccines/administration & dosage , Cancer Vaccines/therapeutic use , Cell Line, Tumor , Cell Membrane/chemistry , Mice , Mice, Inbred C57BL , Microfluidics/methods , Tumor Microenvironment/immunology
13.
Biomaterials ; 185: 322-332, 2018 12.
Article in English | MEDLINE | ID: mdl-30267958

ABSTRACT

Orally administrable drug delivery vehicles are developed to manage incurable inflammatory bowel disease (IBD), however, their therapeutic outcomes are compromised by the side effects of systemic drug exposure. Herein, we use hyaluronic acid functionalized porous silicon nanoparticle to bridge enzyme-responsive hydrogel and pH-responsive polymer, generating a hierarchical structured (nano-in-nano-in-micro) vehicle with programmed properties to fully and sequentially overcome the multiple obstacles for efficiently delivering drugs locally to inflamed sites of intestine. After oral administration, the pH-responsive matrix protects the embedded hybrid nanoparticles containing drug loaded hydrogels against the spatially variable physiological environments of the gastrointestinal tract until they reach the inflamed sites of intestine, preventing premature drug release. The negatively charged hybrid nanoparticles selectively target the inflamed sites of intestine, and gradually release drug in response to the microenvironment of inflamed intestine. Overall, the developed hierarchical structured and programmed vehicles load, protect, transport and release drugs locally to inflamed sites of intestine, contributing to superior therapeutic outcomes. Such strategy could also inspire the development of numerous hierarchical structured vehicles by other porous nanoparticles and stimuli-responsive materials for the local delivery of various drugs to treat plenty of inflammatory gastrointestinal diseases, including IBD, gastrointestinal cancers and viral infections.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Budesonide/administration & dosage , Delayed-Action Preparations/chemistry , Inflammatory Bowel Diseases/drug therapy , Intestines/drug effects , Silicon/chemistry , Administration, Oral , Animals , Anti-Inflammatory Agents/pharmacokinetics , Anti-Inflammatory Agents/therapeutic use , Budesonide/pharmacokinetics , Budesonide/therapeutic use , Cell Line , Drug Delivery Systems , Humans , Hyaluronic Acid/analogs & derivatives , Hydrogen-Ion Concentration , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/pathology , Intestines/immunology , Intestines/pathology , Male , Mice, Inbred C57BL , Nanoparticles/chemistry , Polymers/chemistry , Porosity
14.
Adv Drug Deliv Rev ; 131: 3-21, 2018 06.
Article in English | MEDLINE | ID: mdl-29738786

ABSTRACT

The use of drug nanocrystals in the drug formulation is increasing due to the large number of poorly water-soluble drug compounds synthetized and due to the advantages brought by the nanonization process. The downsizing processes are done using a top-down approach (milling and homogenization currently employed at the industrial level), while the crystallization process is performed by bottom-up techniques (e.g., antisolvent precipitation, use of supercritical fluids or spray and freeze drying). In addition, the production of nanocrystals in confined environment can be achieved within microfluidics channels. This review analyzes the processes for the preparation of nanocrystals and co-crystals, divided by top-down and bottom-up approaches, together with their combinations. The combination of both strategies merges the favorable features of each process and avoids the disadvantages of single processes. Overall, the applicability of drug nanocrystals is highlighted by the widespread research on the production processes at the engineering, pharmaceutical, and nanotechnology level.


Subject(s)
Nanoparticles/chemistry , Pharmaceutical Preparations/chemical synthesis , Chromatography, Supercritical Fluid , Crystallization , Humans , Nanotechnology , Pharmaceutical Preparations/chemistry
15.
Adv Mater ; 30(24): e1703740, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29534311

ABSTRACT

In the past two decades, porous silicon (PSi) has attracted increasing attention for its potential biomedical applications. With its controllable geometry, tunable nanoporous structure, large pore volume/high specific surface area, and versatile surface chemistry, PSi shows significant advantages over conventional drug carriers. Here, an overview of recent progress in the use of PSi in drug delivery and cancer immunotherapy is presented. First, an overview of the fabrication of PSi with various geometric structures is provided, with particular focus on how the unique geometry of PSi facilitates its biomedical applications, especially for drug delivery. Second, surface chemistry and modification of PSi are discussed in relation to the strengthening of its performance in drug delivery and bioimaging. Emerging technologies for engineering PSi-based composites are then summarized. Emerging PSi advances in the context of cancer immunotherapy are also highlighted. Overall, very promising research results encourage further exploration of PSi for biomedical applications, particularly in drug delivery and cancer immunotherapy, and future translation of PSi into clinical applications.


Subject(s)
Neoplasms/therapy , Drug Delivery Systems , Humans , Immunotherapy , Porosity , Silicon
16.
Adv Drug Deliv Rev ; 128: 54-83, 2018 03 15.
Article in English | MEDLINE | ID: mdl-28801093

ABSTRACT

Nanoparticulate drug delivery systems hold great potential for the therapy of many diseases, especially cancer. However, the translation of nanoparticulate drug delivery systems from academic research to industrial and clinical practice has been slow. This slow translation can be ascribed to the high batch-to-batch variations and insufficient production rate of the conventional preparation methods, and the lack of technologies for rapid screening of nanoparticulate drug delivery systems with high correlation to the in vivo tests. These issues can be addressed by the microfluidic technologies. For example, microfluidics can not only produce nanoparticles in a well-controlled, reproducible, and high-throughput manner, but also create 3D environments with continuous flow to mimic the physiological and/or pathological processes. This review provides an overview of the microfluidic devices developed to prepare nanoparticulate drug delivery systems, including drug nanosuspensions, polymer nanoparticles, polyplexes, structured nanoparticles and theranostic nanoparticles. We also highlight the recent advances of microfluidic systems in fabricating the increasingly realistic models of the in vivo milieu for rapid screening of nanoparticles. Overall, the microfluidic technologies offer a promise approach to accelerate the clinical translation of nanoparticulate drug delivery systems.


Subject(s)
Drug Delivery Systems , Microfluidic Analytical Techniques , Nanomedicine , Nanoparticles/chemistry , Translational Research, Biomedical , Drug Delivery Systems/instrumentation , Humans , Microfluidic Analytical Techniques/instrumentation
17.
Adv Mater ; 30(24): e1703393, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29024054

ABSTRACT

Herein, a novel nanohybrid based on porous silicon, gold nanoparticles (Au NPs), and acetalated dextran (DPSi/DAu@AcDEX) is reported to encapsulate and deliver one drug and increase the computer tomography (CT) signal for acute-liver-failure (ALF) theranostics. A microfluidic-assisted method is used to co-encapsulate different NPs in a single step. By alternating the surface properties of different NPs and by modulating the composition of the organic phase, both PSi and Au NPs are effectively encapsulated into the polymer matrix simultaneously, thus further achieving a multifunctional application. This system can be used to identify pathologically changes in the tissues and selectively deliver drugs to these sites. The loading of a therapeutic compound (XMU-MP-1) improves the drug solubility, precise, in situ drug delivery, and the drug-functioning time. In vivo results confirm a superior treatment effect and better compliance of this newly developed nanoformulation than free compound. This nanosystem plays a crucial role in targeting the lesion area, thus increasing the local drug concentration important for ALF reverse-effect. Moreover, the residence of Au NPs within the matrix further endows our system for CT-imaging. Altogether, these results support that this nanohybrid is a potential theranostic platform for ALF.


Subject(s)
Nanoparticles , Dextrans , Gold , Humans , Liver Failure, Acute , Liver Regeneration , Silicon , Theranostic Nanomedicine
18.
Lab Chip ; 17(11): 1856-1883, 2017 05 31.
Article in English | MEDLINE | ID: mdl-28480462

ABSTRACT

The microfluidic technique has brought unique opportunities toward the full control over the production processes for drug delivery carriers, owing to the miniaturisation of the fluidic environment. In comparison to the conventional batch methods, the microfluidic setup provides a range of advantages, including the improved controllability of material characteristics, as well as the precisely controlled release profiles of payloads. This review gives an overview of different fluidic principles used in the literature to produce either polymeric microparticles or nanoparticles, focusing on the materials that could have an impact on drug delivery. We also discuss the relations between the particle size and size distribution of the obtained carriers, and the design and configuration of the microfluidic setups. Overall, the use of microfluidic technologies brings exciting opportunities to expand the body of knowledge in the field of controlled drug delivery and great potential to clinical translation of drug delivery systems.


Subject(s)
Drug Carriers , Drug Delivery Systems , Microfluidic Analytical Techniques , Animals , Cell Line , Humans , Mice
19.
Adv Mater ; 29(7)2017 Feb.
Article in English | MEDLINE | ID: mdl-28009461

ABSTRACT

Immunoadjuvant porous silicon (PSi)-based nanovaccines are prepared by nanoprecipitation in a glass capillary microfluidics device. Vesicles, derived from cancer cell membranes encapsulating thermally oxidized PSi nanoparticles or PSi-polymer nanosystems binding a model antigen, are biocompatible over a wide range of concentrations, and show immunostimulant properties in human cells, promoting the expression of co-stimulatory signals and the secretion of pro-inflammatory cytokines.


Subject(s)
Silicon/chemistry , Cell Membrane , Dextrans , Humans , Immunotherapy , Neoplasms , Porosity
20.
Nanomedicine (Lond) ; 11(19): 2471-81, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27622305

ABSTRACT

AIM: To investigate porous silicon (PSi) nanoparticles (NPs) behavior in the embryonic brain. MATERIALS & METHODS: Fluorescently labeled PSi NPs were injected into the embryonic brains intraventricularly and to the mother intravenously (iv.). Brain histology from different time points up to 3 days was analyzed and live brains imaged with two-photon microscopy. RESULTS: PSi NPs were able to penetrate 80% of the embryonic cortical depth. Particle motility was confirmed in real-time in vivo. PSi NPs were able to penetrate the embryonic cortex after either iv. maternal or intraventricular injection. No developmental of macromorphological changes or increased cell apoptosis was observed. CONCLUSION: PSi NPs penetrate deep in the brain tissues of embryos after intraventricular injection and after iv. injection to the mother.


Subject(s)
Brain/metabolism , Maternal-Fetal Exchange , Nanoparticles/metabolism , Silicon/metabolism , Animals , Brain/diagnostic imaging , Brain/drug effects , Diffusion , Embryo, Mammalian/metabolism , Female , Humans , Injections, Intravenous , Injections, Intraventricular , Mice, Inbred C57BL , Nanoparticles/chemistry , Nanoparticles/toxicity , Porosity , Pregnancy , Silicon/chemistry , Surface Properties , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...